Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Common Stock Issued
Cash raised by issuing new shares.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Common Stock Issued · Q4 FY2025 · quarter ended Dec 2025
Common stock issued declines year over year
Q4 FY2025 common stock issued of $888K fell 67.7% year over year. Sequentially, it fell 74.5% from the prior quarter.
Context
- Common stock issued increased in 1 of the last 2 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 4.47M USD
- Year-over-year change
- -39.0%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.47M | -39.0% |
| FY2024 | 2024-12-31 | 7.32M | — |
| FY2023 | 2023-12-31 | 0 | — |
Common Stock Issued vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's FY2025 common stock issued of $4.47M is the smallest of the 8 companies compared; the peer median is $50.88M.
- Its year-over-year change of -39.0% is the 5th highest of 6, against a peer median of +33293.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $360.66M | — | +869.3% | — | |
| LTM Mar 2026 | $170.67M | +54062.1% | -89.4% | 1436.2% | |
| LTM Mar 2026 | $102.13M | +7762.1% | +65.6% | 329448.4% | |
| LTM Mar 2026 | $50.88M | -51.5% | -16.6% | 180.3% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $50.07M | — | — | — |
| LTM Mar 2026 | $37.38M | +42373.9% | -88.3% | — | |
| LTM Mar 2026 | $27.59M | +33293.9% | — | 99.6% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $4.47M | -39.0% | — | — |
| Peer median (excluding PLYX) | $50.88M | +33293.9% | -16.6% | 808.3% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 3.24M | 2.4M | 0 |
| Change in Working Capital | 369K | (621K) | 316K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | (52K) | (401K) | 398K |
| Other Working Capital | 421K | (220K) | (82K) |
| Other Non-Cash Items | 0 | 26M | 4.73M |
| Operating Cash Flow | (173K) | (2.57M) | (3.94M) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 |
| Debt Repayment | 128K | (128K) | 0 |
| Common Stock Issued | 0 | 7.32M | 4.47M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 128K | 7.19M | 4.47M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (45K) | 4.62M | 522K |
| Free Cash Flow | (173K) | (2.57M) | (3.94M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.